Sign up


Match Document Document Title
9034841 Modulation of hepatitis B virus (HBV) expression  
Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate...
9034329 Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof  
The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment;...
9029340 Radiation sensitization agents for prostate cancer  
Compositions and methods are provided for sensitizing neoplastic cells to radiotherapy. The invention provides aptamer-inhibitory nucleic acid chimeras that selectively inliibit the expression of...
9029337 Modulation of factor 7 expression  
Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an...
9029339 Impaired wound healing compositions and methods  
Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods,...
9029525 Compositions and methods for inhibiting expression of GSK-3 genes  
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3.
9029341 RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)  
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene...
9023824 Composition for inhibiting angiogenesis containing a peroxidasin inhibitor as an active ingredient  
The invention relates to a composition for angiogenesis inhibition comprising a peroxidasin inhibitor as an effective ingredient, and more particularly, to a method of screening angiogenesis...
9023823 Micro-RNA's that regulate muscle cells  
The present invention describes microRNAs that regulate the differentiation, proliferation and death of cardiac and skeletal muscles cells. These molecules represent unique targets in the...
9023825 Materials and methods related to modulation of mismatch repair and genomic stability by miR-155  
The present invention provides materials and methods related to modulation of mismatch repair and genomic stability by miR-155.
9023820 Compositions and methods for silencing apolipoprotein C-III expression  
The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or...
9018184 Inhibitors of SP140 and their use in therapy  
A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of bromodomain-containing protein: SP140.
9018183 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions  
The invention relates to methods and compositions for the treatment/and or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).
9018185 Method of diagnosing cancer using a nucleolin specific aptamer  
Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease,...
9018187 Cationic lipids and methods for the delivery of therapeutic agents  
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that...
9018179 Methods and compositions for RNAi mediated inhibition of gene expression in mammals  
Methods and compositions are provided for modulating, e.g., reducing, expression of a target sequence in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent,...
9018180 CD44 splice variants in neurodegenerative diseases  
There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of...
9018186 Method of treating hyperproliferation of cells using a nucleolin specific aptamer  
Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease,...
9018188 MicroRNA inhibitors  
The present invention relates to microRNAs (miRNAs) that are associated with obesity. The present invention is directed to methods, compounds, and compositions for preventing and treating obesity,...
9012423 Methods for treatment of alport syndrome  
Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves...
9012425 Methods for the treatment of Leber congenital amaurosis  
The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to...
9012419 Methods and compositions related to eosinophil regulation  
Disclosed are compositions and methods for regulating eosinophils.
9012418 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA)  
Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to...
9012140 Target-dependent nucleic acid adapter  
In accordance with the present invention, there is provided a nucleic acid target-dependent adapter linked to a nucleic acid sequence. The adapter comprises linked together a biosensor having a...
9011903 Cationic lipids for therapeutic agent delivery formulations  
Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are...
9012139 Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of...
9012225 Lipophilic polynucleotide conjugates  
Disclosed are lipophilic polynucleotide conjugates including polynucleotide-cholesterol conjugates and methods of delivering therapeutic polynucleotides to a mammalian cell or patient in need of...
9012420 Aptamer for chymase, and use thereof  
Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and...
9012426 Pharmaceutical anti-angiogenic composition including a MicroRNA-382 inhibitor  
The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the...
9012421 Bicyclic cyclohexose nucleic acid analogs  
The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing...
9006198 Selective reduction of allelic variants  
Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods,...
9006206 Composition and methods for modulating cell proliferation and cell death  
Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
9006195 Regulation of hematopoietic stem cell functions through microRNAs  
The present disclosure relates to regulation of functions of hematopoietic stem cells (HSCs) by delivering of miRNAs, including miR-125b, miR-126, and miR-155, to HSCs. For example, in some...
9006204 Aptamers for prion diagnostics and aptamer binding detection system  
There is disclosed PrPSc aptamers. There is further disclosed PrPSc aptamers. There is further disclosed an infectious agent or neurodegenerative disease bifunctional aptamer comprising a first...
9006201 Prophylactic or therapeutic agent for diabetes  
The present invention provides a prophylactic or therapeutic drug for diabetes, which contains a polynucleotide such as miR-199b* and the like. Moreover, the present invention provides a method for...
9006197 Compositions and methods for inhibiting expression of Eg5 and VEGF genes  
This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and...
9006199 Methods and compositions for treating prostate cancer  
Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
9006196 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases  
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical...
9006205 Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor GW4869 for degenerative neurological disorders  
Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy...
9006202 Method and compositions for treating HIV infection  
A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or ...
9006200 MicroRNA-based approach to treating malignant pleural mesothelioma  
The invention relates to microRNA mimics, corresponding to the miR-15/107 family, and to methodology for using microRNA mimics to treat malignant pleural mesothelioma (MPM) by restoring regulation...
9006192 RNAi methods and compositions for stimulating proliferation of cells with adherent junctions  
Described herein are methods and compositions for stimulating proliferation of cells that express adherent junctions and cease proliferation, for example, human corneal endothelial cells, by...
9006191 Silencing of polo-like kinase expression using interfering RNA  
The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to...
9005906 Tetrahydropyran nucleic acid analogs  
The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran...
9006194 Compositions and methods for diminishing viral infection and inflammation associated with viral infection  
The invention relates to compositions and methods for preventing and diminishing virus infection. The invention further relates to compositions and methods for diminishing inflammation associated...
8999943 Antigene oligomers inhibit transcription  
Transcription of a gene in a mammalian cell is methylase-independently inhibited by contacting the cell with a nucleic acid oligomer of 12-28 bases complementary for a partially single-stranded...
8999950 Compositions and methods for silencing aldehyde dehydrogenase  
The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid...
8999945 Methods, compositions and systems for local delivery of drugs  
Implantable medical device eluting drug locally and in a prolonged fashion are provided.
8999944 Thioredoxin interacting protein (TXNIP) as regulator of vascular function  
The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by...
8993528 Oligomeric compounds comprising tricyclic nucelosides and methods for their use  
The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided...